Alexion’s Voydeya gains FDA approval for extravascular haemolysis

02 Apr 2024
www.pharmaceutical-technology.com
Phase 3Fast TrackClinical ResultPhase 2Drug Approval
Alexion’s Voydeya gains FDA approval for extravascular haemolysis
Preview
Source: Pharmaceutical Technology
Alexion is exploring the potential of Voydeya as a monotherapy. Credit: Sai Thaw Kyar/Shutterstock.com.
Alexion, AstraZeneca Rare Disease has received approval from the US Food and Drug Administration (FDA) for Voydeya (danicopan) as an add-on therapy to treat extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).
A first-in-class, oral Factor D inhibitor, Voydeya has been developed for patients who continue to suffer from EVH despite treatment with C5 inhibitorsC5 inhibitors such as Ultomiris (ravulizumab) or Soliris (eculizumab).
The FDA’s decision is grounded in the positive outcomes of the ALPHA Phase III trial, which demonstrated that Voydeya met its primary endpoint of haemoglobin change from baseline to week 12, alongside all key secondary endpoints.
The drug was generally well-tolerated with no new safety concerns.
As part of the ALPHA double-blind, placebo-controlled, multiple-dose trial, patients were enrolled and randomised to receive Voydeya or placebo apart from their ongoing Soliris or Ultomiris therapy over 12 weeks.
See Also:
US FDA grants fast track status to LISCure’s LB-P8 drug for PSC
Alexion’s Voydeya gains FDA approval for extravascular haemolysis
Preview
Source: Pharmaceutical Technology
FDA extends review period for Applied Therapeutics’ govorestat NDA
Alexion’s Voydeya gains FDA approval for extravascular haemolysis
Preview
Source: Pharmaceutical Technology
It aimed to assess the superiority of Voydeya as an adjunct to C5 inhibitorC5 inhibitor therapy.
The trial included a prespecified interim analysis and an option for a two-year extension period for those completing the initial 24 weeks.
Japan already approved Voydeya and the European Union is poised to follow suit.
The drug has also achieved breakthrough therapy designation in the US and PRIority MEdicines (PRIME) status in the EU.
Alexion CEO Marc Dunoyer stated: “The approval of first-in-class, Factor D inhibitor Voydeya marks an important advancement in the treatment of PNH and builds on our leadership and commitment to bring forward innovation in complement science.
“As the ALPHA trial suggests, dual complement pathway inhibition at Factor D and C5 may be an optimal treatment approach for this subset of patients with EVH, enabling them to continue with proven standard-of-care therapy.”
Alexion is also exploring Voydeya’s potential as a monotherapy for geographic atrophy in a Phase II clinical trial.
The FDA recently approved Alexion’s Ultomiris to treat adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.